Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
This study compared the relative bioavailability (rate and extent of absorption) of 0.4 mg/35
mcg Norethindrone and Ethinyl Estradiol Chewable Tablets by Teva Pharmaceuticals, USA with
that of 0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets manufactured by Warner Chilcott Company,
Inc., following a single oral dose (2 * 0.4 mg/35 mcg chewable tablets) in healthy female
adult volunteers administered under fasting conditions.